{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T17:07:34Z","timestamp":1744650454356,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012399","name":"U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201200013I","HHSO100201200013I"],"award-info":[{"award-number":["HHSO100201200013I","HHSO100201200013I"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI128821","R01 AI128821"],"award-info":[{"award-number":["R01 AI128821","R01 AI128821"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human infections with avian H7N9 subtype influenza viruses are a major public health concern and vaccines against H7N9 are urgently needed for pandemic preparedness. In early 2013, novel H7N9 influenza viruses emerged in China that caused about 1600 human cases of infection with a high associated case fatality rate. In this study, two H7N9 split virion vaccines with or without AS03 adjuvant were tested in the naive ferret model. Serological analyses demonstrated that homologous hemagglutination inhibition and microneutralization antibody titers were detectable in the ferrets after the first immunization with the AS03-adjuvanted vaccines that were further boosted by the second immunization. In addition, heterologous antibody titers against older H7 subtype viruses of the North American lineage (H7N7, H7N3) and newer H7 subtype viruses of the Eurasian lineage (H7N9) were detected in the animals receiving the AS03-adjuvanted vaccines. Animals receiving two immunizations of the AS03-adjuvanted vaccines were protected from weight loss and fever in the homologous challenge study and had no detectable virus in throat or lung samples. In addition, microscopic examination post-challenge showed animals immunized with the AS03-adjuvanted vaccines had the least signs of lung injury and inflammation, consistent with the greater relative efficacy of the adjuvanted vaccines. In conclusion, this study demonstrated that the AS03-adjuvanted H7N9 vaccines elicited high levels of homologous and heterologous antibodies and protected against H7N9 virus damage post-challenge.<\/jats:p>","DOI":"10.1038\/s41541-021-00299-3","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T13:05:27Z","timestamp":1616159127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6792-7650","authenticated-orcid":false,"given":"Daniel","family":"Stadlbauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon de","family":"Waal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Strohmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin J. B. Veldhuis","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Boutet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D. M. E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-7248","authenticated-orcid":false,"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5568-5420","authenticated-orcid":false,"given":"Raffael","family":"Nachbagauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koert J.","family":"Stittelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8111","authenticated-orcid":false,"given":"Corey P.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"299_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095\u20132128 (2012).","journal-title":"Lancet"},{"unstructured":"World Health Organisation. Influenza at the Human-Animal Interface. Summary and Assessment (2018).","key":"299_CR2"},{"key":"299_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cr.2017.154","volume":"28","author":"K Subbarao","year":"2017","unstructured":"Subbarao, K. Avian influenza H7N9 viruses: a rare second warning. Cell Res. 28, 1\u20132 (2017).","journal-title":"Cell Res."},{"key":"299_CR4","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1017\/S0950268815001570","volume":"143","author":"WD Tanner","year":"2015","unstructured":"Tanner, W. D., Toth, D. J. & Gundlapalli, A. V. The pandemic potential of avian influenza A(H7N9) virus: a review. Epidemiol. Infect. 143, 3359\u20133374 (2015).","journal-title":"Epidemiol. Infect."},{"doi-asserted-by":"publisher","unstructured":"Quan, C. et al. New threats from H7N9 influenza virus: spread and evolution of high- and low-pathogenicity variants with high genomic diversity in wave five. J. Virol. https:\/\/doi.org\/10.1128\/JVI.00301-18 (2018).","key":"299_CR5","DOI":"10.1128\/JVI.00301-18"},{"key":"299_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.15585\/mmwr.mm6635a2","volume":"66","author":"JC Kile","year":"2017","unstructured":"Kile, J. C. et al. Update: increase in human infections with novel Asian lineage avian influenza A(H7N9) viruses during the fifth epidemic - China, October 1, 2016\u2013August 7, 2017. MMWR Morb. Mortal. Wkly Rep. 66, 928\u2013932 (2017).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"299_CR7","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.chom.2017.09.008","volume":"22","author":"M Imai","year":"2017","unstructured":"Imai, M. et al. A highly pathogenic avian H7N9 influenza virus isolated from A human is lethal in some ferrets infected via respiratory droplets. Cell Host Microbe 22, 615\u2013626 (2017).","journal-title":"Cell Host Microbe"},{"doi-asserted-by":"publisher","unstructured":"Yang, L. et al. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in Mainland China. J. Virol. https:\/\/doi.org\/10.1128\/jvi.01277-17 (2017).","key":"299_CR8","DOI":"10.1128\/jvi.01277-17"},{"key":"299_CR9","first-page":"137","volume":"385","author":"S Herfst","year":"2014","unstructured":"Herfst, S., Imai, M., Kawaoka, Y. & Fouchier, R. A. Avian influenza virus transmission to mammals. Curr. Top. Microbiol. Immunol. 385, 137\u2013155 (2014).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"299_CR10","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3201\/eid2011.140897","volume":"20","author":"J Li","year":"2014","unstructured":"Li, J. et al. Human co-infection with avian and seasonal influenza viruses, China. Emerg. Infect. Dis. 20, 1953\u20131955 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"299_CR11","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3201\/eid2312.170798","volume":"23","author":"A Marinova-Petkova","year":"2017","unstructured":"Marinova-Petkova, A. et al. Avian influenza A(H7N2) virus in human exposed to sick cats, New York, USA, 2016. Emerg. Infect. Dis. 23, 2046\u20132049 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"299_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/ni.3684","volume":"18","author":"R Nachbagauer","year":"2017","unstructured":"Nachbagauer, R. et al. Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat. Immunol. 18, 464\u2013473 (2017).","journal-title":"Nat. Immunol."},{"doi-asserted-by":"publisher","unstructured":"Hai, R. et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat. Commun. https:\/\/doi.org\/10.1038\/ncomms3854 (2013).","key":"299_CR13","DOI":"10.1038\/ncomms3854"},{"key":"299_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/infdis\/jiw414","volume":"214","author":"A Madan","year":"2016","unstructured":"Madan, A. et al. Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults. J. Infect. Dis. 214, 1717\u20131727 (2016).","journal-title":"J. Infect. Dis."},{"doi-asserted-by":"publisher","unstructured":"Baras, B. et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0001401 (2008).","key":"299_CR15","DOI":"10.1371\/journal.pone.0001401"},{"key":"299_CR16","doi-asserted-by":"publisher","first-page":"e01113","DOI":"10.1128\/mBio.01113-18","volume":"9","author":"RA Albrecht","year":"2018","unstructured":"Albrecht, R. A. et al. Moving forward: recent developments for the ferret biomedical research model. mBio 9, e01113\u2013e01118 (2018).","journal-title":"mBio"},{"key":"299_CR17","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.vaccine.2010.12.128","volume":"29","author":"B Baras","year":"2011","unstructured":"Baras, B. et al. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 29, 2092\u20132099 (2011).","journal-title":"Vaccine"},{"key":"299_CR18","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1016\/j.vaccine.2013.06.071","volume":"31","author":"JH Kreijtz","year":"2013","unstructured":"Kreijtz, J. H. et al. Low pathogenic avian influenza A(H7N9) virus causes high mortality in ferrets upon intratracheal challenge: a model to study intervention strategies. Vaccine 31, 4995\u20134999 (2013).","journal-title":"Vaccine"},{"key":"299_CR19","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2013.6589","volume":"309","author":"MT Osterholm","year":"2017","unstructured":"Osterholm, M. T., Ballering, K. S. & Kelley, N. S. Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). JAMA 309, 2557\u20132558 (2017).","journal-title":"JAMA"},{"key":"299_CR20","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","volume":"368","author":"R Gao","year":"2013","unstructured":"Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368, 1888\u20131897 (2013).","journal-title":"N. Engl. J. Med."},{"key":"299_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3201\/eid2002.131094","volume":"20","author":"L Guo","year":"2014","unstructured":"Guo, L. et al. Human antibody responses to avian influenza A(H7N9) virus, 2013. Emerg. Infect. Dis. 20, 192\u2013200 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"299_CR22","doi-asserted-by":"publisher","first-page":"e00502","DOI":"10.1128\/mSphere.00502-17","volume":"2","author":"D Stadlbauer","year":"2017","unstructured":"Stadlbauer, D. et al. Vaccination with a recombinant H7 hemagglutinin-based influenza virus vaccine induces broadly reactive antibodies in humans. mSphere 2, e00502\u2013e00517 (2017).","journal-title":"mSphere"},{"key":"299_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11684-017-0602-z","volume":"11","author":"D Stadlbauer","year":"2017","unstructured":"Stadlbauer, D., Nachbagauer, R., Meade, P. & Krammer, F. Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses? Front. Med. 11, 471\u2013479 (2017).","journal-title":"Front. Med."},{"key":"299_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41426-018-0115-0","volume":"7","author":"D Stadlbauer","year":"2018","unstructured":"Stadlbauer, D., Amanat, F., Strohmeier, S., Nachbagauer, R. & Krammer, F. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A\/Shanghai\/1\/2013 (H7N9) protect against novel H7 virus isolates in the mouse model. Emerg. Microbes Infect. 7, 110 (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"299_CR25","first-page":"e00375","volume":"92","author":"H Yang","year":"2018","unstructured":"Yang, H. et al. Structural and molecular characterization of the hemagglutinin from the fifth-epidemic-wave A(H7N9) influenza viruses. J. Virol. 92, e00375\u201300318 (2018).","journal-title":"J. Virol."},{"key":"299_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-0187-4","volume":"5","author":"JD Jonge","year":"2020","unstructured":"Jonge, J. D. et al. H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets. npj Vaccines 5, 1\u201314 (2020).","journal-title":"npj Vaccines"},{"key":"299_CR27","doi-asserted-by":"publisher","first-page":"81012","DOI":"10.18632\/oncotarget.12746","volume":"7","author":"H Ou","year":"2016","unstructured":"Ou, H. et al. Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A\/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine. Oncotarget 7, 81012\u201381025 (2016).","journal-title":"Oncotarget"},{"key":"299_CR28","doi-asserted-by":"publisher","first-page":"91828","DOI":"10.18632\/oncotarget.20064","volume":"8","author":"H Ou","year":"2017","unstructured":"Ou, H. et al. Longevity of protective immune responses induced by a split influenza A (H7N9) vaccine mixed with MF59 adjuvant in BALB\/c mice. Oncotarget 8, 91828\u201391840 (2017).","journal-title":"Oncotarget"},{"doi-asserted-by":"publisher","unstructured":"Duan, Y. et al. Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0099322 (2014).","key":"299_CR29","DOI":"10.1371\/journal.pone.0099322"},{"doi-asserted-by":"publisher","unstructured":"Yang, X. et al. Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0123659 (2015).","key":"299_CR30","DOI":"10.1371\/journal.pone.0123659"},{"doi-asserted-by":"publisher","unstructured":"Rudenko, L. et al. Two live attenuated vaccines against recent low\u2013and highly pathogenic H7N9 influenza viruses are safe and immunogenic in ferrets. Vaccines https:\/\/doi.org\/10.3390\/vaccines6040074 (2018).","key":"299_CR31","DOI":"10.3390\/vaccines6040074"},{"key":"299_CR32","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1016\/j.vaccine.2015.07.026","volume":"33","author":"P Pushko","year":"2015","unstructured":"Pushko, P. et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus. Vaccine 33, 4975\u20134982 (2015).","journal-title":"Vaccine"},{"doi-asserted-by":"publisher","unstructured":"Hekele, A. et al. Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect. https:\/\/doi.org\/10.1038\/emi.2013.54 (2013).","key":"299_CR33","DOI":"10.1038\/emi.2013.54"},{"key":"299_CR34","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316\u20131327 (2017).","journal-title":"Mol. Ther."},{"key":"299_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/erv.11.192","volume":"11","author":"N Gar\u00e7on","year":"2012","unstructured":"Gar\u00e7on, N., Vaughn, D. & Didierlaurent, A. Development and evaluation of AS03, an adjuvant system containing \u03b1-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11, 349\u2013366 (2012).","journal-title":"Expert Rev. Vaccines"},{"doi-asserted-by":"publisher","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. https:\/\/doi.org\/10.3791\/51112 (2013).","key":"299_CR36","DOI":"10.3791\/51112"},{"key":"299_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043603","volume":"7","author":"F Krammer","year":"2012","unstructured":"Krammer, F. et al. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS ONE 7, e43603 (2012).","journal-title":"PLoS ONE"},{"doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Sobrido, L. & Garc\u00eda-Sastre, A. Generation of recombinant influenza virus from plasmid DNA. JoVE https:\/\/doi.org\/10.3791\/2057 (2010).","key":"299_CR38","DOI":"10.3791\/2057"},{"key":"299_CR39","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.vaccine.2006.08.036","volume":"25","author":"JH Kreijtz","year":"2007","unstructured":"Kreijtz, J. H. et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25, 612\u2013620 (2007).","journal-title":"Vaccine"},{"key":"299_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0166-0934(98)00071-8","volume":"74","author":"GF Rimmelzwaan","year":"1998","unstructured":"Rimmelzwaan, G. F., Baars, M., Claas, E. C. & Osterhaus, A. D. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J. Virol. Methods 74, 57\u201366 (1998).","journal-title":"J. Virol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00299-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:30:16Z","timestamp":1670023816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00299-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00299-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"type":"electronic","value":"2059-0105"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"6 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following interests are relevant to the submitted work. E.B., P.B., B.L.I., and C.P.M. are, or were at the time of the study, employees of the GSK group of companies. P.B. and C.P.M. report ownership of GSK shares and\/or restricted GSK shares. B.L.I. and C.P.M. are listed as an inventor on patents owned by the GSK group of companies. The remaining authors declare that there are no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}